Suzanne Schindler

, MD, PhD

Associate Professor of Neurology, Washington University School of Medicine

Dr. Suzanne E. Schindler is a clinical neurologist and neuroscientist focused on improving the diagnosis and treatment of Alzheimer disease. She completed the MD/PhD program at Washington University, where she studied the basic biology of apolipoprotein E metabolism in the laboratory of Dr. David Holtzman. Dr. Schindler then trained in clinical neurology at Washington University and completed a fellowship in dementia under Drs. John Morris, Anne Fagan, and Marc Diamond. Currently, Dr. Schindler sees patients with memory concerns, coordinates biomarker testing for the Washington University Memory Diagnostic Center, and attends on the inpatient neurology consult service. She leads the Fluid Biomarker Core for the Knight Alzheimer Disease Research Center and a project for the Adult Children Study. She received a large R01 to evaluate the relationships between plasma biomarkers, other biomarker measures, and symptomatic Alzheimer disease. She works closely with Dr. Randall Bateman on validation of novel fluid biomarkers. She is very interested in translating research findings into clinical practice. Further, she has a particular focus on understanding and reducing disparities in healthcare.

Dr. Schindler has served on a Scientific Advisory Board for Eisai.

Read more

This Speaker's Sessions

Tuesday Oct. 17
2:30–3:15 PM ET
Watch Replay
Now Live!

New Technologies for Early Detection and Diagnosis of Alzheimer’s

Scaling up technologies for early detection of Alzheimer’s pathology and cognitive impairment promises to transform the global response to Alzheimer’s disease. Digital biomarkers and fluid biomarkers (ranging from cerebrospinal fluid to blood) to detect the disease are advancing rapidly in clinical practice and will enable a more simple, timely, and accurate Alzheimer’s diagnosis.  Key Question: What do these tools and technologies mean for patients and their doctors?

View SessionWatch Replay